Share Price | Pyxis Oncology, Inc. Stock Analysis & Recommendation

Q: What does Pyxis Oncology, Inc. do?

Overview:Pyxis Oncology, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) Market cap: USD 73.72 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.02 Return on Equity: -72.03% Price to Book: 0.71 Contact Details:Details: No Company Details Available Registrar Address: Not available.

Q: Is Pyxis Oncology, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Pyxis Oncology, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.81, an EV to EBIT of 0.25, and an EV to EBITDA of 0.26. In comparison to peers, Eton Pharmaceuticals, Inc. has a significantly higher EV to EBITDA of 187.8463, while Ocugen, Inc. shows an EV to EBITDA of -6.1838, highlighting Pyxis's relative valuation challenges.Despite a strong recent performance with a 1-month return of 87.1% compared to the S&P 500's 2.33%, the long-term outlook remains concerning, as the 1-year return of -36.61% starkly contrasts with the S&P 500's 17.14%. This suggests that while short-term gains may attract attention, the overall valuation metrics indicate that Pyxis Oncology, Inc. is currently overvalued.

Q: Is Pyxis Oncology, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Pyxis Oncology, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the RSI is bearish, indicating some divergence in momentum. Moving averages on the daily timeframe remain bullish, but the monthly KST is bearish, suggesting caution. Additionally, the Bollinger Bands show a bullish signal weekly but a mildly bearish signal monthly. In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 24.73% and 87.1% respectively, but has underperformed over the past year with a return of -36.61% compared to the S&P 500's 17.14%. Overall, the mixed signals and recent trend change suggest a cautious approach.

Results Declared: Pyxis Oncology, Inc. has declared results on 23 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

189.54 k

Shareholding (Dec 2025)

FII

5.79%

Held by 40 FIIs

DII

71.02%

Held by 14 DIIs

Promoter

13.74%

How big is Pyxis Oncology, Inc.?

22-Jun-2025

As of Jun 18, Pyxis Oncology, Inc. has a market capitalization of 73.72 million and reported net sales of 0.00 million with a net profit of -95.23 million for the latest four quarters. The balance sheet shows shareholder's funds of 120.75 million and total assets of 157.18 million.

View full answer

What does Pyxis Oncology, Inc. do?

22-Jun-2025

Pyxis Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $73.72 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -72.03%.

View full answer

Is Pyxis Oncology, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Pyxis Oncology, Inc. is considered risky and overvalued despite a recent 87.1% one-month return, with concerning long-term performance reflected in a -36.61% one-year return compared to the S&P 500's 17.14%.

View full answer

Is Pyxis Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Pyxis Oncology, Inc. shows a neutral trend with mixed indicators, having recently shifted from mildly bullish to sideways, while significantly outperforming the S&P 500 in the short term but underperforming over the past year, suggesting a cautious approach.

View full answer

Compare Pyxis Oncology, Inc. with Similar Stocks

GlycoMimetics, Inc.Relmada Therapeutics, Inc.DiaMedica Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Sep 25

NET SALES(9M) At USD 2.82 MM has Grown at -82.53%
ROCE(HY) Lowest at -87.28%
PRE-TAX PROFIT(Q) Lowest at USD -22 MM

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 104 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-110.68%

Price to Book

1.51

Revenue and Profits:

Net Sales:

11 Million

(Quarterly Results - Dec 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

28.83%

6 Months

-30.58%

1 Year

24.35%

2 Years

-60.82%

3 Years

-35.29%

4 Years

-69.57%

5 Years

0.0%

Pyxis Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

30.74%

EBIT Growth (5y)

-342.70%

EBIT to Interest (avg)

-65.66

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.08

Tax Ratio

2.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

67.57%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.51

EV to EBIT

-0.33

EV to EBITDA

-0.34

EV to Capital Employed

-3.81

EV to Sales

9.89

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-110.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 22 Schemes (9.45%)

Foreign Institutions

Held by 40 Foreign Institutions (5.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 49.16% vs -128.21% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.40",
          "val2": "-18.60",
          "chgp": "17.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-21.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.10",
          "val2": "-35.60",
          "chgp": "49.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,657.50%",
          "val2": "0.00%",
          "chgp": "-165.75%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -13.66% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2.98% vs -4.74% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.90",
          "val2": "16.10",
          "chgp": "-13.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-79.90",
          "val2": "-65.50",
          "chgp": "-21.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-21.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-79.60",
          "val2": "-77.30",
          "chgp": "-2.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,091.80%",
          "val2": "-4,242.30%",
          "chgp": "-184.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

11.00

0.00

Operating Profit (PBDIT) excl Other Income

-15.40

-18.60

17.20%

Interest

0.00

Exceptional Items

0.00

-21.00

100.00%

Consolidate Net Profit

-18.10

-35.60

49.16%

Operating Profit Margin (Excl OI)

-1,657.50%

0.00%

-165.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 49.16% vs -128.21% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

13.90

16.10

-13.66%

Operating Profit (PBDIT) excl Other Income

-79.90

-65.50

-21.98%

Interest

0.00

Exceptional Items

0.00

-21.00

100.00%

Consolidate Net Profit

-79.60

-77.30

-2.98%

Operating Profit Margin (Excl OI)

-6,091.80%

-4,242.30%

-184.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -13.66% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -2.98% vs -4.74% in Dec 2024

All Annual Results

Company CV

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available